Futura Medical PLC Director/PDMR Shareholding (7662I)
12 Agosto 2019 - 09:21AM
UK Regulatory
TIDMFUM
RNS Number : 7662I
Futura Medical PLC
12 August 2019
12 August 2019
Futura Medical plc
("Futura" or the "Company")
Director/PDMR Shareholding
Futura Medical plc (AIM: FUM), the innovative healthcare company
focused on advanced transdermal technology, announces the following
change in the non-beneficial ownership of the ordinary shares in
the Company held by James Barder, the Company's Chief
Executive.
Futura today received notification that Mr. Barder has resigned
as a trustee of a family trust. No Futura shares have been sold or
distributed by the trust.
As a result, Mr Barder's non-beneficial holding is revised to
117,500 ordinary shares. His beneficial holding remains unchanged
at 968,472 ordinary shares with an aggregate beneficial and
non-beneficial holding of 1,085,972 ordinary shares, representing
approximately 0.53% per cent. of the Company's issued share
capital.
Further details are contained within the notification below,
made in accordance with Article 19 of the EU Market Abuse
Regulation 596/2014.
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Liberum
Bidhi Bhoma/ Euan Brown/ Kane Collings
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal Dermasys(R) drug delivery technology.
These products are optimised for clinical efficacy, safety,
administration and patient convenience and are developed for the
prescription and consumer healthcare markets as appropriate.
Current therapeutic areas are sexual health, including erectile
dysfunction, and pain relief. Development and commercialisation
strategies are designed to maximise product differentiation and
value creation whilst minimising risk.
The first European Phase 3 study for MED2005, referred to as
"FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised,
double blind, placebo-controlled, home use, parallel group study of
MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment
of erectile dysfunction with an open label extension. FM57 is
progressing on track, with headline data expected by the end of
2019.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name James Barder
----------------------------------- ------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Chief Executive Officer
----------------------------------- ------------------------------------
b) Initial notification/Amendment Initial notification
----------------------------------- ------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Futura Medical plc
----------------------------------- ------------------------------------
b) LEI 21380053QLT46UNV2303
----------------------------------- ------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of the financial Ordinary Shares of 0.2 pence each
instrument, type of instrument
GB0033278473
Identification code
----------------------------------- ------------------------------------
b) Nature of the transaction Change in non-beneficial holding
as a result of resignation from
a family trust.
----------------------------------- ------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
N/A 117,500
----------
----------------------------------- ------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
----------------------------------- ------------------------------------
e) Date of the transaction 12 August 2019
----------------------------------- ------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------------- ------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHLLFLSTAIFLIA
(END) Dow Jones Newswires
August 12, 2019 10:21 ET (14:21 GMT)
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024